Fig. 7

BCL2 inhibition improves ARQ 531 in vivo activity. a Kaplan–Meier survival curve in the MOLM-13 xenograft after mice were treated with vehicle (N = 9) or 50 mg/kg ARQ 531 Q.D.P.O (N = 9) or 75 mg/kg venetoclax Q.D.P.O (N = 10) or 50 mg/kg ARQ 531 and 75 mg/kg venetoclax combination Q.D.P.O (N = 10) at 4 days post engraftment until ERC. b Noninvasive serial whole body bioluminescence imaging of ventral view to monitor leukemia progression and regression post treatment. Mice were injected with 150 mg/kg Firefly D-Luciferin for evaluation of tumor burden as determined by whole body bioluminescence imaging using IVIS imager